That's not true, closer to $2.90.
However, the corporate activity that would follow post FDA approval, will be ravenous, it will be efficient and it will be take hold at a speed the retail investor is not accustomed to.
It's rather convenient that a bit of consternation has been tossed into the mix regarding glysophate in the moments before an FDA approval is delivered, or not delivered. Certainly makes shorting the stock quite attractive in the short term, the effect lowering the price for a long term hold.
Nufarm are on the cusp of a monumental development, why not take it down a few pegs to get some cheap seats for the main party...
That's not true, closer to $2.90.However, the corporate activity...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.59 |
Change
-0.050(1.89%) |
Mkt cap ! $992.0M | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.64 | $2.57 | $4.451M | 1.714M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | $2.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.60 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| NUF (ASX) Chart |